该新药为集团(即公司及控股子公司/单位，下同)自主研发的化学药品。该新药主要用于与5-氟尿嘧啶和亚叶酸(甲酰四氢)联合应用于转移性结直肠癌的一线治疗、原发肿瘤完全切除后的III期(Duke’sC期)结肠癌的辅助治疗、以及不适合手术切除或局部治疗的局部晚期和转移的肝细胞癌(HCC)的治疗，与卡培他滨联合(XELOX)用于II期或III期胃腺癌患者根治切除术后的辅助化疗。fosun pharma (02196) rose more than 11% in early trading, as of the press release, up 11.05%, at 18.7 Hong Kong dollars, with a turnover of 0.1 billion Hong Kong dollars.
According to the Wise Financial News APP, Fosun Pharma (02196) rose more than 11% in early trading, as of the press release, up 11.05%, at 18.7 Hong Kong dollars, with a turnover of 0.1 billion Hong Kong dollars.
On the news front, Fosun Pharma announced that its controlling subsidiary, Gismo (Wuhan) Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the market registration application of Oxaliplatin Injection (referred to as the new drug).
The new drug is a chemical drug independently developed by the group (i.e. the company and its controlling subsidiaries/units). The new drug is mainly used in combination with fluorouracil and leucovorin (methotrexate) for the first-line treatment of metastatic colorectal cancer, adjuvant therapy in stage III (Duke’sC stage) colon cancer after primary tumor resection, and for the treatment of locally advanced and metastatic hepatocellular carcinoma (HCC) not amenable to surgical resection or local therapy, in combination with capecitabine (XELOX) for adjuvant chemotherapy after radical resection surgery in II or III stage gastric adenocarcinoma patients.
As of August 2024, the Group has invested approximately RMB 3.52 million (unaudited) in research and development for this new drug. According to the latest data from IQVIA CHPA, in 2023, the sales of Oxaliplatin injection approved for marketing in China (excluding Hong Kong, Macao, and Taiwan) amounted to approximately RMB 2.297 billion.
